Mission Statement, Vision, & Core Values (2024) of Alnylam Pharmaceuticals, Inc. (ALNY).

An Overview of Alnylam Pharmaceuticals, Inc. (ALNY)

General Summary of Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. (ALNY) was founded in 2002 and is headquartered in Cambridge, Massachusetts. The company is a leader in the development of RNA interference (RNAi) therapeutics, focusing on genetically defined diseases. Alnylam has developed a robust pipeline of therapies targeting various conditions, including hereditary ATTR amyloidosis and acute hepatic porphyria.

As of 2024, Alnylam's commercialized products include:

• ONPATTRO (patisiran) - approved for the treatment of hereditary ATTR amyloidosis.
• AMVUTTRA (vutrisiran) - also for hereditary ATTR amyloidosis.
• GIVLAARI (givosiran) - for the treatment of acute hepatic porphyria.
• OXLUMO (lumasiran) - for the treatment of primary hyperoxaluria type 1.

In 2024, Alnylam reported global net product revenues of $1.195 billion, reflecting a significant increase from prior years, driven primarily by strong sales of AMVUTTRA and GIVLAARI.

Company's Financial Performance in the Latest Financial Reports

For the third quarter of 2024, Alnylam Pharmaceuticals generated total revenues of $500.9 million, compared to $750.5 million in the same quarter of 2023, a decrease of 33%. However, the nine-month revenue for 2024 was $1.655 billion, up 19% from $1.389 billion in 2023.

Net product revenues for the third quarter of 2024 were $420.1 million, reflecting a 34% increase year-over-year. Notably, AMVUTTRA sales contributed $258.6 million, a 74% increase from the previous year.

Operating costs for the same quarter totaled $577.8 million, an 8% increase compared to $536.7 million in Q3 2023. Research and development expenses accounted for $270.9 million, while selling, general, and administrative expenses were $221.0 million.

Alnylam reported a net loss of $111.6 million in Q3 2024, compared to a net income of $147.8 million in Q3 2023. This decline in profitability was attributed to increased operational expenses and a decrease in collaboration revenues, particularly with Roche.

Introduction to Company as a Leader in the Industry

Alnylam Pharmaceuticals is recognized as a pioneer in the RNAi therapeutics industry, leveraging its proprietary platform to develop innovative treatments for rare diseases. The company has established significant partnerships with major pharmaceutical firms, enhancing its research capabilities and expanding its market reach.

As of 2024, Alnylam is well-positioned as a leader in its field, with a diverse pipeline and a strong commitment to addressing unmet medical needs. The company's focus on RNAi technology has the potential to revolutionize treatment paradigms for various genetic disorders, underscoring its significance in the biotechnology landscape.

Mission Statement of Alnylam Pharmaceuticals, Inc. (ALNY)

Mission Statement of Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals, Inc. is dedicated to transforming the lives of patients with genetic diseases through the innovative use of RNA interference (RNAi) therapeutics. The company's mission statement encapsulates its commitment to pioneering science, rigorous research, and the delivery of high-quality therapeutic solutions.

Core Component 1: Innovation

Innovation is a cornerstone of Alnylam's mission. The company focuses on developing revolutionary RNAi therapeutics that target the root causes of genetic diseases. In 2024, Alnylam reported total product revenues amounting to $1.195 billion, reflecting a robust pipeline of innovative therapies such as ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. This revenue demonstrates the successful commercialization of their innovative products, which are designed to provide transformative treatment options for patients.

Core Component 2: Commitment to Quality

Alnylam's mission emphasizes a strong commitment to quality in its products and services. The company adheres to stringent regulatory standards and conducts extensive clinical trials to ensure the safety and efficacy of its therapies. As of September 30, 2024, Alnylam's total assets were valued at approximately $4.205 billion, showcasing its financial stability and capacity to invest in quality research and development. Furthermore, the company has incurred research and development expenses of $826 million for the nine months ended September 30, 2024, underscoring its dedication to developing high-quality therapeutic solutions.

Core Component 3: Patient-Centric Approach

The final component of Alnylam's mission is a patient-centric approach. The company prioritizes the needs and well-being of patients in its research and development processes. In the third quarter of 2024, Alnylam achieved global net product revenues of $420.1 million, reflecting the impact of its therapies on patients' lives. The company actively engages with patient communities to understand their needs better and to ensure that its therapeutic solutions address the most pressing health challenges faced by individuals with genetic diseases.

This commitment to innovation, quality, and patient-centricity drives Alnylam Pharmaceuticals in its mission to lead the field of RNAi therapeutics and to make a meaningful difference in the lives of patients worldwide.

Vision Statement of Alnylam Pharmaceuticals, Inc. (ALNY)

Vision Statement of Alnylam Pharmaceuticals, Inc. (ALNY)

As of 2024, Alnylam Pharmaceuticals, Inc. (ALNY) has articulated its vision statement focusing on becoming a top-tier biopharmaceutical company dedicated to delivering transformative RNA interference (RNAi) therapeutics. This vision is structured around several core components that emphasize innovation, patient impact, and sustainable growth.

Alnylam aims to provide transformative medicines for patients with rare and prevalent diseases through its innovative RNAi technology. The company has launched several products, achieving significant revenues:

For the nine months ended September 30, 2024, total net product revenues amounted to $1.2 billion, highlighting the company's commitment to addressing unmet medical needs.

Alnylam's vision underscores a strong focus on rare diseases, aiming to develop therapies that can significantly improve patient outcomes. The company has established a robust pipeline that includes:

• Late-stage clinical programs for ATTR amyloidosis and Alzheimer’s disease.
• Multiple investigational RNAi therapeutics targeting various tissue types.
• Strategic collaborations with major pharmaceutical companies to enhance research and development efforts.

As of September 30, 2024, Alnylam reported an accumulated deficit of $7.20 billion, reflecting its extensive investments in research and development to support its vision.

Alnylam is committed to sustainable innovation in the biopharmaceutical sector. The company is actively pursuing the following strategic goals:

• Enhancing its existing product portfolio through ongoing clinical trials.
• Investing in cutting-edge technologies to improve drug delivery systems.
• Expanding its commercial infrastructure globally to reach more patients.

In 2024, Alnylam's total revenues, including collaboration revenues, reached $1.66 billion, demonstrating the effectiveness of its innovative approach and strategic collaborations.

Alnylam's financial performance reflects its vision of growth and expansion in the biotech industry. Key financial metrics include:

These figures indicate a strong liquidity position, which supports Alnylam's ongoing research and development initiatives.

At the core of Alnylam's vision is a deep commitment to patients. The company actively seeks to engage with patient communities and stakeholders to ensure that its therapeutic developments align with patient needs and expectations. This commitment is reflected in:

• Patient-centric clinical trial designs.
• Collaboration with advocacy groups to raise awareness about rare diseases.
• Transparent communication about the potential risks and benefits of its therapies.

Alnylam's mission is to ensure that every patient has access to innovative treatments that can transform their lives.

Core Values of Alnylam Pharmaceuticals, Inc. (ALNY)

Commitment to Patients

This core value emphasizes the central role of patients in Alnylam Pharmaceuticals' mission. The company continuously strives to develop innovative therapies that address unmet medical needs.

In the third quarter of 2024, Alnylam reported global net product revenues of $420.1 million from its commercialized products, including ONPATTRO and AMVUTTRA, which are aimed at treating rare diseases. This revenue reflects the company's commitment to delivering effective treatments to patients who rely on their therapies.

Innovation

Innovation is vital for Alnylam, driving the development of new RNAi therapeutics. The company invests significantly in research and development to maintain its competitive edge.

Alnylam's R&D expenses for the nine months ended September 30, 2024, were approximately $826.1 million, highlighting the substantial resources allocated to advancing its innovative pipeline.

Collaboration

Collaboration with leading pharmaceutical companies enhances Alnylam's ability to innovate and deliver new therapies. Partnerships provide access to additional resources and expertise.

As of September 30, 2024, Alnylam had collaboration revenues of $403.3 million, primarily derived from its agreements with Roche and Novartis, showcasing the effectiveness of its collaborative approach.

Integrity

Integrity underpins Alnylam's operations, ensuring transparency and ethical conduct in all business practices.

The company has consistently maintained high standards of compliance, reflected in its rigorous adherence to regulatory requirements during clinical trials and product launches, which is critical for maintaining trust with stakeholders.

Excellence

Alnylam strives for excellence in all aspects of its operations, from research and development to customer service.

In 2024, the company's ONPATTRO received accolades for its effectiveness in treating hereditary transthyretin-mediated amyloidosis, reinforcing Alnylam's commitment to high-quality outcomes.

Article updated on 8 Nov 2024

Resources:

• Alnylam Pharmaceuticals, Inc. (ALNY) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Alnylam Pharmaceuticals, Inc. (ALNY)' financial performance, including balance sheets, income statements, and cash flow statements.
• SEC Filings – View Alnylam Pharmaceuticals, Inc. (ALNY)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.